Marion Webb
Managing Editor
Marion Webb has been writing about health care issues for nearly two decades as a full-time reporter and freelancer. As the senior business reporter for the San Diego Business Journal, Marion covered new medical innovations at San Diego’s top-ranking research institutions and the medical device and life sciences industry for nearly eight years. She’s also been a regular contributor to the Los Angeles County Medical Association’s Physician Magazine and Physicians News Network focusing on new technologies, practice management, reimbursement and other trendy issues relevant to physician practices and their ability to succeed. She remains fascinated by the ever-growing numbers of innovative products coming out of the medtech sector, from potentially life-saving devices to help treat patients who otherwise wouldn’t have access to medical care to breakthrough technologies that benefit mankind. Marion earned her BA in communications from UC San Diego and continues to enjoy an active lifestyle in San Diego.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Marion Webb
New Real-World Data Show Benefits Of Abbott's FreeStyle Libre Technology
New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.
Grail Starts PATHFINDER Trial To Evaluate Multi-Cancer Blood Test For Early Cancer Detection
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Device Week, 12 February 2020 – A Close-Up On AbioMed's Plan To Counter Unfavorable Impella Data
In this edition of Device Week, Medtech Insight's managing editor Marion Webb talks with deputy editor Reed Miller about his recent story on Abiomed's plan to counter unfavorable studies of its Impella heart pump.
[Editor's note: This article was updated on 14 February 2020 to clarify that Abiomed has invested more than $100m over the past five years in clinical research on the Impella heart pump platform. Abiomed has not committed to spend another $100m on new physician education and communication programs.]
Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs
BioIntelliSense is getting ready to trial its newly FDA-cleared BioSticker in patients at Colorado-based hospital network UCHealth for remote monitoring of vital signs.
Boston Scientific Expects Up To $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020
Boston Scientific said in an earnings call it expects the coronavirus outbreak may lead to a $10m to $40m loss in first-quarter sales as a result of lower procedures volumes and disrupted supply chains in China. For the fourth quarter, Boston Scientific reported $2.9bn in sales.